tenofovir alafenamide/emtricitabine/dolutegravir (single-tablet regimen)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for tenofovir alafenamide/emtricitabine/dolutegravir (single-tablet regimen), covering 2024-02-28 to 2024-02-28. Get the full timeline:
Most recent: Clinical Trial Update: Switching From Protease Inhibitor/Ritonavir to Generic Single Tablet Regimen of Tenofovir Alafenamide/Emtricitibine/Dolutegravir [Phase 3]